GlassScriptPhysician profile
Shashi Mohan Alloju
NPI 1518282060
$8,599.68
in general payments reported to CMS, 2019-2025
33 companies · $366 in 2025
The $366 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $231 · 2021: $1,281 · 2022: $1,577 · 2023: $3,904 · 2024: $869 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,800 · Food and Beverage: $2,004 · Travel and Lodging: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,800.00 |
| Food and Beverage | $2,004.27 |
| Travel and Lodging | $334.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,868.74 | 2020-2025 | Argos, Ngenuity, Unity |
| Biotissue Holdings INC. | $1,558.12 | 2021-2024 | |
| Sun Pharmaceutical Industries INC. | $393.78 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $360.94 | 2022-2024 | Ic-8 Apthera Iol, Envista Mx60 Iol, Miebo |
| Beaver-Visitec International, INC. | $299.55 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $236.59 | 2021-2024 | Eq Workplace |
| Notal Vision, INC. | $234.34 | 2022 | |
| Sight Sciences, INC. | $228.46 | 2020-2025 | Sion Surgical Instrument, Omni Surgical System |
| Johnson & Johnson Surgical Vision, INC. | $221.65 | 2019-2023 | Tecnis Iol |
| Allergan, INC. | $186.83 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $157.40 | 2019-2021 | |
| Abbvie INC. | $124.60 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $99.20 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $71.39 | 2021-2023 | |
| Harrow Eye, LLC | $69.90 | 2024-2025 | Vevye |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $56.89 | 2020-2021 | |
| Tandem Diabetes Care, INC. | $46.97 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $43.45 | 2024 | Tepezza |
| Oyster Point Pharma, INC. | $43.31 | 2022-2023 | Tyrvaya |
| Valeritas, INC. | $37.80 | 2019 | |
| Aerie Pharmaceuticals, INC. | $36.93 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $26.40 | 2019 | |
| Alcon Research LLC | $22.26 | 2019 | |
| Lilly USA, LLC | $22.25 | 2023 | Jardiance |
| Dompe US, INC. | $21.50 | 2019 | |
| Rayner Intraocular Lenses Limited | $21.43 | 2024 | Omidria |
| Astellas Pharma US INC | $20.91 | 2024 | Izervay |
| Mallinckrodt Hospital Products INC. | $17.20 | 2020 | |
| Zealand Pharma US, INC. | $15.64 | 2021 | |
| Rxsight INC | $15.20 | 2022 | |
| Dexcom, INC. | $15.12 | 2023 | Dexcom G6 Transmitter |
| Eyevance Pharmaceuticals LLC | $13.27 | 2021 | |
| Kala Pharmaceuticals, INC. | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shashi Alloju listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.